Towards vaccine equity: Should big pharma waive intellectual property rights for COVID-19 vaccines?

Towards vaccine equity: Should big pharma waive intellectual property rights for COVID-19 vaccines?

Detalles Bibliográficos
Autor principal:	Melody Okereke
Formato:	Artículo
Lenguaje:	English
Publicado:	Elsevier 2021-11-01
Colección:	Public Health in Practice
Materias:	Big Pharma COVID-19 Vaccine Equity LMICs IP Rights Patent
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2666535221000902

Ejemplares similares

The WTO and the Covid‐19 “Vaccine Apartheid”: Big Pharma and the Minefield of Patents
por: Stéphane Paquin, et al.
Publicado: (2023-03-01)

Big Pharma, Big Business
por: Sorin-George Toma, et al.
Publicado: (2021-01-01)

Should Pharma Companies Waive Their COVID-19 Vaccine Patents? A Legal and Ethical Appraisal
por: Tammy Cowart, et al.
Publicado: (2023-05-01)

Legal Decision Support: Exploring Big Data Analytics Approach to Modeling Pharma Patent Validity Cases
por: Viju Raghupathi, et al.
Publicado: (2018-01-01)

COVID-19 vaccines, public health goods and Catholic social teaching: Why justice must prevail over charity in the global vaccine distribution
por: Vivencio O. Ballano
Publicado: (2022-01-01)

Business models of big pharma in Russia: A pharmaceutical value chain perspective
por: Natalia A. Volgina
Publicado: (2022-03-01)

Editorial: Intellectual Property Rights (December 2011)
por: Chris McPhee, et al.
Publicado: (2011-12-01)

Vaccine equity in low and middle income countries: a systematic review and meta-analysis
por: Huda Ahmed Ali, et al.
Publicado: (2022-06-01)

The artificial intelligence pharma era after “Chat Generative Pre-trained Transformer”
por: Xie Zhengwei, et al.
Publicado: (2023-06-01)

Comparing Multivariate with Wealth-Based Inequity in Vaccination Coverage in 56 Countries: Toward a Better Measure of Equity in Vaccination Coverage
por: Bryan N. Patenaude, et al.
Publicado: (2023-02-01)

Pharma industry social communication in Italy: quantitative and qualitative analysis of data from a Social Observatory
por: Francesco Tissoni, et al.
Publicado: (2021-06-01)

Intellectual property in the bio-sector research:
por: Stephany Soto
Publicado: (2020-03-01)

Words for pharma: a quantitative and qualitative analysis on vision, mission and values of multinational pharma companies.
por: Giulio Zuanetti, et al.
Publicado: (2020-04-01)

EXAMINATION OF IMPACT OF PHARMA R&D ON PROFITABILITY
por: Gergo Tomori
Publicado: (2014-07-01)

A New Frontier in the Fight Against Cancer (That Is, for Those Who Can Afford It)
por: Jennifer Gumer
Publicado: (2018-01-01)

The Right to Try
por: Jacqueline Augenstein
Publicado: (2020-06-01)

Exzellenz in der Bildung für eine innovative Schweiz: Die Position des Wirtschaftsdachverbandes Chemie Pharma Biotech
por: Marcel Sennhauser
Publicado: (2018-02-01)

Purdue Pharma Deceptive Research Misconduct
por: Jason Sanchez Alonso
Publicado: (2021-02-01)

Heterogeneous Catalysis to Drive the Waste-to-Pharma Concept: From Furanics to Active Pharmaceutical Ingredients
por: Rafael Luque, et al.
Publicado: (2021-11-01)

BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Management
por: Victor G. Rodwin, et al.
Publicado: (2018-03-01)

Farming for Pharming: Novel Hydroponic Process in Contained Environment for Efficient Pharma-Grade Production of Saffron
por: Luca Nardi, et al.
Publicado: (2022-12-01)

A Returnable Transport Item to Integrate Logistics 4.0 and Circular Economy in Pharma Supply Chains
por: Gerald Schneikart, et al.
Publicado: (2023-01-01)

SB-17
por: Michael Reaves
Publicado: (2018-09-01)

The Gender Gap in Pharmaceutical Research
por: Elisabeth Armstrong
Publicado: (2018-09-01)

Extrusion for pharma applications: An update
por: Maël Gallas, et al.
Publicado: (2023-01-01)

Keine Apotheke, kein Pharma, sondern ein Enabler
por: Peter Stegmaier
Publicado: (2024-10-01)

Features of intellectual property protection mechanisms on the example of orphan drugs circulation
por: D. S. Yurochkin, et al.
Publicado: (2022-01-01)

Effects of physician-led medication reconciliation on the outcomes of outpatients utilizing the PharmaCloud system
por: Ya-Yuan Yu, et al.
Publicado: (2025-02-01)

How to Provide Feedback to Students' Learning – Assignment and Feedback Concept in the Blended Learning Environment pharma2
por: Christina Weber, et al.
Publicado: (2006-02-01)

Improving End-to-End Traceability and Pharma Supply Chain Resilience with Blockchain
por: Corinne Sim, et al.
Publicado: (2022-08-01)

Pharma 4.0-Artificially Intelligent Digital Twins for Solidified Nanosuspensions
por: Christina Davidopoulou, et al.
Publicado: (2022-10-01)

Pharma-Nutritional Properties of Olive Oil Phenols. Transfer of New Findings to Human Nutrition
por: M. Carmen Crespo, et al.
Publicado: (2018-06-01)

Blockchain based solution for secure information sharing in pharma supply chain management
por: Adla Padma, et al.
Publicado: (2024-11-01)

Transparency in Negotiation of European Union With Big Pharma on COVID-19 Vaccines
por: Salvatore Sciacchitano, et al.
Publicado: (2021-02-01)

Bad medicine
por: Richard Smith
Publicado: (2012-12-01)

The Circumstances Behind Involuntary Hospitalization
por: Tara Wilkes
Publicado: (2019-03-01)

Pharma Sector under the Influence of the Parafiscal Mechanism: Clawback Tax
por: Nicoleta Asalos, et al.
Publicado: (2023-08-01)

Bridging the Strategic Gap Between Biotech and Pharma Companies
por: Gudrun Tiedemann
Publicado: (2004-11-01)

A Network Modeling and Analysis Approach for Pharma Industry Regulatory Assessment
por: Theodosia Charitou, et al.
Publicado: (2024-01-01)

Global Vaccine Equity to End the COVID-19 Pandemic: A Canadian Perspective and Call to Action
por: Michael Clarke, et al.
Publicado: (2022-01-01)